Last reviewed · How we verify
OAMs
OAMs are oral antidiabetic agents that work through multiple mechanisms to improve glycemic control.
OAMs are oral antidiabetic agents that work through multiple mechanisms to improve glycemic control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | OAMs |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Therapeutic area | Endocrinology/Diabetes |
| Phase | Phase 3 |
Mechanism of action
OAMs (Oral Antidiabetic Medications) is a broad category rather than a single drug entity. Eli Lilly's phase 3 OAM candidates typically include agents targeting insulin secretion, insulin sensitivity, or glucose metabolism. Without a specific compound identifier, the exact mechanism cannot be precisely defined, but Lilly's pipeline in this space includes GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbances
- Hypoglycemia
- Weight changes
Key clinical trials
- A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes (PHASE3)
- A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting
- A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment (PHASE3)
- A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus (PHASE3)
- A Study in Patients With Type 2 Diabetes Mellitus (PHASE3)
- A Study in Adults With Type 2 Diabetes (PHASE3)
- A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus (PHASE3)
- Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OAMs CI brief — competitive landscape report
- OAMs updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI